Loading...
XNASPLSE
Market cap1.11bUSD
Dec 27, Last price  
18.02USD
1D
-3.79%
1Q
4.74%
Jan 2017
177.23%
IPO
341.67%
Name

Pulse Biosciences Inc

Chart & Performance

D1W1MN
XNAS:PLSE chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
22.98%
Rev. gr., 5y
%
Revenues
0k
-100.00%
00000001,418,000700,0000
Net income
-42m
L-28.40%
-474,857-2,811,283-9,518,000-25,567,000-37,545,000-45,988,000-49,737,000-63,160,000-58,953,000-42,210,000
CFO
-33m
L-29.72%
-173,143-3,316,768-8,051,000-11,087,000-23,896,000-34,185,000-35,365,000-54,097,000-47,013,000-33,041,000
Earnings
Mar 26, 2025

Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
URL
https://www.pulsebiosciences.com/
IPO date
May 18, 2016
Employees
61
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
700
-50.63%
1,418
 
Cost of revenue
44,781
58,757
64,432
Unusual Expense (Income)
NOPBT
(44,781)
(58,057)
(63,014)
NOPBT Margin
Operating Taxes
448
(500)
Tax Rate
NOPAT
(44,781)
(58,505)
(62,514)
Net income
(42,210)
-28.40%
(58,953)
-6.66%
(63,160)
26.99%
Dividends
Dividend yield
Proceeds from repurchase of equity
16,789
15,862
57,507
BB yield
-2.86%
-16.87%
-13.89%
Debt
Debt current
2,116
1,813
1,210
Long-term debt
17,230
84,184
20,854
Deferred revenue
62,275
Other long-term liabilities
(65,000)
(3,255)
Net debt
(25,019)
27,583
(3,295)
Cash flow
Cash from operating activities
(33,041)
(47,013)
(54,097)
CAPEX
(121)
(401)
(437)
Cash from investing activities
(121)
(401)
7,563
Cash from financing activities
16,388
79,939
62,685
FCF
(43,542)
(56,574)
(62,552)
Balance
Cash
44,365
61,139
28,614
Long term investments
(2,725)
(3,255)
Excess cash
44,365
58,379
25,288
Stockholders' equity
(336,860)
(294,668)
(236,171)
Invested Capital
391,422
365,652
279,856
ROIC
ROCE
EV
Common stock shares outstanding
48,038
33,935
27,964
Price
12.24
341.88%
2.77
-81.30%
14.81
-37.93%
Market cap
587,985
525.52%
94,000
-77.30%
414,147
-25.34%
EV
562,966
121,583
410,852
EBITDA
(43,574)
(56,702)
(61,868)
EV/EBITDA
Interest
1,364
448
646
Interest/NOPBT